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Abstract
The objective of this investigation was to determine
the efficacy of several novel agents in preventing lung
tumorigenesis inmice.We evaluated polyphenonE, red
ginseng, and rapamycin in A/J mice treated with the
tobacco-specific carcinogen benzo(a)pyrene for their
ability to inhibit pulmonary adenoma formation and
growth. We found that treatment with polyphenon E
exhibited a significant reduction on both tumor multi-
plicity and tumor load (tumor multiplicity  tumor vol-
ume) in a dose-dependent fashion. Polyphenon E (2%
wt/wt) in the diet reduced tumor multiplicity by 46% and
tumor load by 94%. This result provided key evidence
in support of a phase II clinical chemoprevention trial of
lung cancer. Administration of red ginseng in drinking
water decreased tumor multiplicity by 36% and tumor
load by 70%. The mammalian target of rapamycin in-
hibitor rapamycin showed significant efficacy against
lung tumor growth in the tumor progression protocol
and reduced tumor load by 84%. The results of these
investigations demonstrate that polyphenon E, red gin-
seng, and rapamycin significantly inhibit pulmonary
adenoma formation and growth in A/J mice.
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Introduction
Lung cancer is the leading cause of cancer deaths of men
and women in the United States and western Europe [1].
Epidemiological and laboratory animal model studies have
demonstrated that smoking and environmental exposure
to carcinogens are closely linked to increased lung cancer
risk [2–5]. Tobacco exposure has been implicated in 90%
of lung carcinomas, and smokers have a 20-fold greater
risk of developing lung cancer compared to persons who
have never smoked [6–8]. Chemoprevention is a potentially
important approach used to reduce the large number of
tobacco-caused cancer deaths for both current and former
smokers. Chemoprevention is the use of pharmacologic or
natural agents to inhibit the development of cancer. Nu-
merous studies have found that chemoprevention can prevent
a wide variety of cancers in multiple animal models.
Because of similarities in the histopathology and tumor
progression stages between mouse and human lung adeno-
carcinomas, the mouse lung tumor model has been used ex-
tensively to evaluate the efficacy of putative lung cancer
chemopreventive agents [3,10]. Among the more than 50 dif-
ferent agents tested, several groups of chemicals have shown
significant efficacy against mouse lung tumor development,
including glucocorticoids and isothiocyanates. Glucocorticoids
have proven to be successful during the progression stage of
tumor development, whereas isothiocyanates have proven par-
ticularly effective in blocking carcinogenesis [3,11]. The present
investigation is a continuing effort to develop an effective
chemoprevention of carcinogenesis of the lungs. We evaluated
several novel agents, including polyphenon E, ginseng, and ra-
pamycin, in A/J mice treated with the tobacco-specific carcino-
gen benzo(a)pyrene (BP) for their ability to inhibit pulmonary
adenoma formation and/or growth.
Polyphenon E is a well-standardized decaffeinated green
tea catechin mixture containing five different catechins: epica-
techin, gallocatechin gallate, epigallocatechin, epicatechin gal-
late, and epigallocatechin gallate (EGCG), with EGCG being
the most abundant [12]. Because of the fact that its formulation
is highly reproducible, polyphenon E is the recommended form
of green tea for clinical chemoprevention trials and has been
used in several clinical studies, including an ongoing clinical
phase II study of lung cancer [13,14]. Previously, green tea
in drinking water or topical application has been shown to be
a potent inhibitor of carcinogenesis of the skin, lung, fore-
stomach, esophagus, liver, colon, and mammary glands in ro-
dent models [15,16]. Green tea in drinking water inhibited
carcinogen-induced mouse lung tumorigenesis by 63% [15,16].
Furthermore, green tea was also found to inhibit the growth—or
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to even cause the regression—of established benign skin
tumors, suggesting that it may be preventive against multiple
stages of carcinogenesis [16]. However, the effect of the
administration of polyphenon E in diets on lung tumorigenesis
has not yet been determined.
Ginseng has long been used as a traditional medicine in
Asia to improve physical condition and to prolong life [17].
Ginseng appears to accomplish this by preventing various
diseases such as cancer and diabetes [17]. Epidemiologi-
cal studies suggest that ginseng is a chemopreventive agent
against a variety of cancer types (cancer of the lips, oral
cavity, pharynx, esophagus, stomach, colon, liver, pancreas,
larynx, lung, and ovary) [18–22]. One study showed that
users of ginseng extract had a decreased cancer risk com-
pared to nonusers, and that the decrease was greatly depen-
dent on the frequency of ginseng intake [18]. Another large
cohort study with 4634 (2362 men, 2272 women) adults over
40 years old showed that ginseng users had a decreased risk
(risk ratio = 0.40; 95% CI = 0.28–0.56) of developing several
types of cancers compared to nonusers [21,22]. The general
conclusion from these studies is that ginseng has nontoxic
and non–organ-specific preventive effects against several
types of cancers, including lung cancer. Since 1980, several
researcher groups [23–27] at the Korea Cancer Center Hos-
pital (Seoul, South Korea) have performed a series of rodent
studies using ginseng and have shown that ginseng is a po-
tent inhibitor of lung carcinogenesis in a mouse lung tumor
model using urethane, 7,12-dimethylbenz(a)anthracene
(DMBA), or aflatoxin B1 as a carcinogen. Thus, we sought
to test the efficacy of ginseng in our standard BP-induced
lung tumorigenesis in A/J mice.
Recently, mammalian target of rapamycin (mTOR) inhibi-
tors have received much attention as another group of anti-
cancer drugs [28]. Rapamycin, a natural product derived
from Streptomyces hygroscopicus, is the first defined inhibi-
tor of mTOR [28]. Rapamycin has a strong antitumor activ-
ity through inhibition of mTOR and blocking of cell cycle
progression from G1 to S [28]. One of the mTOR pathway’s
upstream regulators is Akt, which can be activated by phos-
phatidylinositol 3-kinase (PI3K), which in turn is controlled by
PTEN [29]. As a result, tumors with increased mTOR activity
through Akt activation or PTEN mutation are highly suscep-
tible to mTOR inhibition [29]. The significant efficacy of ra-
pamycin’s antitumor activity has been reported in a variety of
human tumor cell lines and animal models of human xeno-
grafts [30,31]. For example, rapamycin and its derivatives
exhibited significant growth inhibition of breast cancer, pros-
tate cancer, leukemia, melanoma, renal cell cancer, glioblas-
toma, and pancreatic cancer cells, and in xenografts [30,31].
Because of the activation of the PI3K/Akt/mTOR pathway in
human and mouse lung tumors, we tested the efficacy of
rapamycin against mouse lung tumor progression.
The goal of this investigation was to discover and de-
velop effective chemopreventive agents against lung tumori-
genesis. We determined the capacity of the three agents
to prevent pulmonary adenoma formation and growth, and
found that polyphenon E, red ginseng, and rapamycin are
potent inhibitors of lung tumorigenesis in A/J mice.
Materials and Methods
Reagents and Animals
BP and tricaprylin were purchased from Sigma Chemical
Co. (St. Louis, MO). The chemopreventive agent polyphenon
E was obtained from Tokyo Food Techno Co., Ltd. (Tokyo,
Japan). Red ginseng extract was obtained from the Korea
Cancer Center Hospital. Rapamycin was purchased from
Wyeth (Philadelphia, PA). Female A/J mice were obtained
from Jackson Laboratories (Bar Harbor, ME) at 6 weeks of
age. Animals were quarantined for 1 week and housed with
wood chip bedding in environmentally controlled, clean-air
rooms with a 12-hour light–dark cycle and a relative humidity
of 50%. Drinking water and diet were supplied ad libitum. The
study was approved by the Washington University’s Institu-
tional Animal Care and Use Committee.
Animal Experiments
Mice were randomly divided into control and treatment
groups with approximately 10 mice per group. All groups
received a single dose of BP (100 mg/kg body weight) in
0.2 ml of tricaprylin through intraperitoneal injection. One
week after the initiation of BP, all mice (except control group)
were treated with polyphenon E for 20 weeks. Mice were
fed 0%. 0.5%, 1.0%, 1.5%, or 2.0% (wt/wt) polyphenon E in
AIN-76A purified powder diet (Dyets, Inc., Bethlehem, PA).
Because mice were somewhat adverse to eating diets con-
taining polyphenon E, we added 3% (wt/wt) sugar to the diet
in all groups, including the control group. All foods were pre-
pared weekly, and feeding jars were cleaned weekly. Foods
were prepared once a week with a powerful KitchenAid (St.
Joseph, MI) mixer running for at least 1 hour. Drinking water
was available ad libitum. The body weights of mice were
measured every 2 weeks for the duration of the study.
Mice were randomly divided into one control group and
two treatment groups. For red ginseng, the first treatment
group was given 10 mg/ml in drinking water, and the second
treatment group was administered 2 mg/ml in drinking water.
The control group received water as control. The red ginseng
in drinking water was changed every other day and was pre-
pared just before water change. Water (control and red gin-
seng) was available ad libitum. Treatments were initiated
1 week before the introduction of carcinogen. After 1 week of
treatment, all groups received a single intraperitoneal dose of
BP (100 mg/kg body weight) in 0.2 ml of tricaprylin. The body
weights of mice were measured every 2 weeks.
For the testing of rapamycin, both control and treat-
ment groups received a single dose of BP (100 mg/kg body
weight) in 0.2 ml of tricaprylin through intraperitoneal injec-
tion. Twelve weeks after the initiation of BP, all mice (except
for the control group) were treated with rapamycin by intra-
peritoneal injection at a dose of 2 mg/kg body weight, five
times a week, for 14 weeks. During the entire assay period,
drinking water was available ad libitum, and the body weights
of mice were measured every 2 weeks.
We monitored the consumption of food and water by
measuring them daily to control the dose of these chemo-
preventive agents. During the study duration, the health
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conditions of mice were monitored everyday, and the body
weights were measured every 2 weeks. We did not observe
any sign of toxicity and loss of body weight. Mice were sac-
rificed 20 to 26 weeks after carcinogen treatment by CO2
asphyxiation. For the phenotyping of lung tumors in all bio-
assays described above, lung tissues were fixed in Tel-
lyesniczky’s solution overnight, followed by 75% EtOH.
Lung tumor development was estimated by two investigators
using a Leica MZ75 dissecting microscope to measure
number (N), volume (V), and total tumor load (NV), as re-
ported previously [32]. Volume calculation was based on the
formula: V (mm3) = 4/3pr3. Histopathological examina-
tions were performed to determine the diagnosis of the
lung tumors.
Statistical Analysis
We hypothesized that BP-induced lung tumors are more
likely to occur in the carcinogen control group than in the
treatment groups. To test this hypothesis, Student’s t test was
used. The data were obtained from the BP control groups and
different treatment groups in each experiment. We applied
square root transformation of tumor numbers because the
original data did not follow normal distribution. The trans-
formed data were of normal distribution (data not shown).
Accordingly, Student’s t test was used to test the differences
between the control group and the treatment groups.
Results
The effect of feeding mice polyphenon E during lung carci-
nogenesis was determined. Beginning 1 week following ini-
tiation by BP, polyphenon E was administered in the diet
at concentrations ranging from 0.5% to 2.0%. Doses of 0.5%,
1.0%, 1.5%, and 2% polyphenon E did not cause any gross
toxicity or significant body weight loss. The incidence of lung
tumor in all BP-treated groups was 100%. BP induced an
average of 10.80 ± 1.86 (n = 10) tumors per mouse in the
control group. Mice treated with 2.0% polyphenon E showed
a significant decrease in tumor multiplicity [46%; 5.89 ±
0.92 (n = 9)] when compared to the control group (P < .05)
(Figure 1B), whereas treatments with 0.5%, 1.0%, and 1.5%
polyphenon E were less effective in decreasing tumor mul-
tiplicities [10.30 ± 2.39 (n = 10), 7.7 ±0.98 (n = 10), and 8.0 ±
0.97 (n = 9), respectively]. In contrast, mice in all treatment
groups showed significant reduction in total tumor load [num-
ber of tumors  volume of tumors] (ranging from P < .01 to
P < .0001). The tumor load in the control group was 3.14 ±
0.66 (mm3; n = 10), whereas the tumor load was 1.11 ± 0.32,
0.68 ± 0.23, 0.33 ± 0.11, and 0.20 ± 0.05 mm3 in groups
treated with 0.5%, 1.0%, 1.5%, and 2.0% polyphenon E, re-
spectively (Figure 1C). We conducted detailed histopatho-
logical examinations to determine the degree of lung tumor
progression related to the effect of the chemopreventive
agent on tumor development. All of the lung nodules were
Figure 1. Effects of polyphenon E on BP-induced lung tumorigenesis in A/J mice. (A) Experimental design. We used the postinitiation protocol. All groups received
a single intraperitoneal dose of BP (100 mg/kg body weight) in 0.2 ml of tricaprylin. One week after the initiation of BP, the control group received AIN-76A diet with
3% sugar. Mice in treatment groups were fed 0.5%, 1.0%, 1.5%, or 2.0% (wt/wt) polyphenon E in AIN-76A diet with 3% sugar for 20 weeks. (B) Effect of
polyphenon E on lung tumor multiplicity. In the 2.0% group, polyphenon E decreased tumor multiplicity by 46%. (C) Effect of polyphenon E on lung tumor load.
Polyphenon E decreased tumor load by 65% (in the 0.5% group), 78% (in the 1.0% group), 90% (in the 1.5% group), and 94% (in the 2.0% group). Error bars
indicate standard error. *P < .05 and ****P < .0001, compared to the control group.
54 Inhibition of Lung Cancer by Polyphenon E, Red Ginseng, and Rapamycin Yan et al.
Neoplasia . Vol. 8, No. 1, 2006
diagnosed as lung adenomas. Lung adenomas are charac-
terized by a monomorphic growth pattern and are generally
comprised of well-differentiated cells but sometimes ex-
hibited a small degree of pleomorphism in slightly larger ade-
nomas (data not shown).
Next, we showed that red ginseng in drinking water
reduced pulmonary tumors. During bioassay, no significant
loss of body weight or signs of gross toxicity were observed
in either treatment group. The incidence of lung tumor was
100% (25/25) in the control group, 96% (24/25) in the low-
dose group (2 mg/ml), and 84% (21/25) in the high-dose
group (10 mg/ml) (Figure 2). BP produced an average of
7.17 ± 0.63 tumors per mouse in A/J mice (n = 25). The aver-
age tumor multiplicity was 6.16 ± 0.59 in the low-dose group
(n = 25) and 4.56 ± 0.69 in the high-dose group (n = 25). The
treatment of red ginseng in the high-dose group decreased
tumor number by 36% (P < .01) (Figure 2B). There was a sig-
nificant decrease in tumor size in both red ginseng treatment
groups. Tumor load was decreased by 41% (P < .05, n = 25) in
the low-dose group (1.46mm3) and by 70% (P < .0001, n = 25)
in the high-dose group (0.74 mm3) when compared to the
control group (2.49 mm3) (Figure 2C). All of the lung nodules
found in experiment 2 were diagnosed as lung adenomas.
Finally, we found that rapamycin is a chemopreventive
agent in the mouse lung tumor carcinogenesis model. As
shown in Figure 3A, 6-week-old A/J mice were randomized
into two groups. The treatment group was given rapamycin
(2 mg/kg, i.p., five times a week) for 12 weeks after carcino-
gen treatment, and this continued for 14 more weeks. The
experiment was terminated 26 weeks after exposure to BP.
We observed that administration of rapamycin reduced both
lung tumormultiplicity and tumor volume in A/Jmice (Figure 3,
BandC). Tumormultiplicity for control animals treatedwith BP
was 11.57 tumors per mouse and decreased to 8.38 tumors
per mouse in mice treated with rapamycin (Figure 3B). Tumor
volume for control animals treated with BPwas 7.38mm3 and
decreased to 1.15 mm3 with rapamycin treatment (P < .01;
Figure 3C). Therefore, administration of rapamycin de-
creased tumor load in mouse lungs by 84% compared to
the control group. All of the lung nodules found were diag-
nosed as lung adenomas.
Discussion
Effective chemoprevention of lung cancer, the principal cause
of cancer deaths in the United States, has not been achieved.
Characterization and use of effective chemopreventive
agents have become important issues in the prevention and
control of this deadly disease, particularly in the case of
former smokers who are known to remain at high risk. Aiming
to identify novel chemopreventive agents for lung cancer, we
have determined the efficacy of several agents, including
polyphenon E, ginseng, and rapamycin, in preventing lung
tumorigenesis in mice and found that these three agents can
significantly inhibit lung tumorigenesis in A/J mice.
Green tea has been shown to be chemopreventive in
several animal models [32–36]. However, the effect of the
administration of polyphenon E in the diet on lung tumori-
genesis has not yet been determined. Polyphenon E is a
well-standardized decaffeinated green tea catechin mixture
Figure 2. Effects of red ginseng extract on BP-induced lung tumorigenesis in A/J mice. (A) Experimental design. We used the complete protocol. After 1 week of
red ginseng treatment, all groups received a single intraperitoneal dose of BP (100 mg/kg body weight). Treatment with red ginseng extract continued for 20 weeks.
(B) Effect of red ginseng extract on lung tumor multiplicity. In the 10-mg/ml group, treatment decreased tumor number by 36%. (C) Effect of red ginseng extract on
lung tumor load. Red ginseng decreased tumor load in a dose-dependent manner (41% and 70% in the 2- and 10-mg/ml groups, respectively). Error bars indicate
standard error. *P < .05, **P < .01, and ****P < .0001, compared to the control group.
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containing five different catechins: epicatechin, gallocatechin
gallate, epigallocatechin, epicatechin gallate, and EGCG [12];
it is the recommended form of green tea for clinical chemo-
prevention trials [13,14]. In this study, we treated the mice with
different concentrations of polyphenon E (0.5%, 1.0%, 1.5%,
and 2%) in AIN-76A diet. We initiated the polyphenon E treat-
ment after BP treatment because green tea in drinking water
was already known to be effective, and because this post-
initiation schedule made the most sense in modeling clinical
trials in former smokers. We found that polyphenon E (2% in
diet) reduced tumor multiplicity by 46% (Figure 1B) and tumor
load by 94% (Figure 1C). The latter result implies that, cumu-
latively, polyphenon E has a profound effect on tumor growth.
Because we have shown that the development of adeno-
carcinomas in this model is highly dependent on tumor size
[32], one would readily hypothesize that this treatment should
profoundly decrease adenocarcinoma formation. We believe
that this is the first report of the efficacy of polyphenon E given
in the diet against lung tumorigenesis in A/J mice, and this
lends strong support to the planned clinical phase II chemo-
prevention study of lung cancer.
The results of administering polyphenon E in the diet are
consistent with many previously reported studies that used
green tea in the drinking water, which showed the inhibi-
tion of carcinogenesis in many rodent models, including the
skin, lung, forestomach, esophagus, liver, colon, and mam-
mary glands [15,16]. Green tea and one of its components
(EGCG), when given in drinking water, have been shown to
inhibit 4-(N-methylnitrosamino)-1-(3-pyridyl)-butanone
(NNK)– induced mouse lung tumorigenesis by 63% and
28%, respectively [37]. Green tea has also been found to in-
hibit the growth—and to cause the regression—of established
benign skin tumors, suggesting that it may be preventive
at all stages of carcinogenesis [16]. Tea polyphenols have
various biologic activities, including antioxidation, modulation
of enzyme systems for metabolizing chemical carcinogens,
inhibition of nitrosation reactions, scavenging of activated
metabolites of chemical carcinogens, and inhibition of tumor
promotion [11,38,39]. Recently, several lines of evidence have
suggested that green tea is a potent inducer of apoptosis in
tumor cell lines [38,39]. It is likely that somedegree of apoptosis
and inhibition of cell proliferation may contribute to achieving
striking decreases in tumor load, which we have observed.
Ginseng has been used for thousands of years in Asia. It
has antioxidant, antitumor promotion, and anti-inflammatory
properties [40]. Ginseng contains more than 30 different
ginsenosides of protopanaxadiol, protopanaxatriol, or olea-
nane [22]. Ginseng is a potent inhibitor of carcinogenesis
in many rodent models, including the lung, skin, liver, mam-
mary gland, uterine cervix, brain, and colon [23–27,41]. The
chemopreventive efficacy of ginseng has been demonstrated
in a mouse lung tumor model using urethane, DMBA, or af-
latoxin B1 as a carcinogen [23–27]—a result that we have
readily confirmed in this standard BP model of lung carcino-
genesis. Furthermore, three specific ginsenosides Rg3, Rg5,
and Rh2 showed a reduction of lung tumor incidence in mice
[17,41]. In a two-stagemouse skinmodel with DMBA, ginseng
exhibited inhibitory effects against the development of skin
papillomas in a dose-dependent manner [42]. When ginseng
was given in the diet, it suppressed preneoplastic lesions
[aberrant crypt foci (ACF)] induced by 1,2-dimethylhydrazine
or azoxymethane [43]. More significantly, ginseng appears to
be effective against ACF development at the postinitiation
stage of colon carcinogenesis [44]. There are some reports
Figure 3. Effects of rapamycin on BP-induced lung tumorigenesis in A/J mice. (A) Experimental design. We used the progression protocol. After 12 weeks of
initiation with a single dose of BP (100 mg/kg body weight), rapamycin was administered with a dose of 2 mg/kg body weight, i.p., for 14 weeks. (B) Effect of
rapamycin on lung tumor multiplicity. As expected, rapamycin did not show significant inhibitory effects on tumor multiplicity (P > .05). (C) Effect of rapamycin on
lung tumor load. Rapamycin decreased tumor load by 84% (P < .01). Error bars indicate standard error. **P < .01, compared to the control group.
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on the mechanisms of the chemopreventive activity of gin-
seng. These studies suggest that the possible actions of gin-
seng are antioxidation, antitumor promotion, induction of p21
or p27, activation of NF-nB, activation of ERK, inhibition of cell
proliferation, and induction of apoptosis [45,46]. In this study,
red ginseng treatment in drinking water did not cause any
gross toxicity and did not affect body weight. Treatment with
red ginseng significantly inhibited both lung tumor multiplicity
and tumor load. Our results demonstrated that red ginseng
was a potent chemopreventive agent for the prevention of lung
tumorigenesis in A/J mice.
Rapamycin is an antifungal agent originally purified from S.
hygroscopicus [28]. It is a drug clinically used to suppress im-
mune response after organ transplantation [28]. Rapamycin
has also been used to inhibit restenosis due to smooth muscle
cell overgrowth after angioplasty. The cellular target of rapa-
mycin has been well characterized [31]. Rapamycin forms a
tight complex with FKBP12, and the rapamycin–FKBP12
complex binds to and inhibits mTOR, which is a protein kinase
[31]. mTOR plays a central role in the regulation of cell growth
andhas been shown todirectly phosphorylateS6Kand4EBP1
[31]. S6K stimulates cell growth by phosphorylating the ri-
bosomal protein S6 and by stimulating translation [47]. S6K
activity is stimulated by mitogens, nutrients, and energy suffi-
ciency [48]. The immunosuppressant drug rapamycin inhibits
S6K activation, which demonstrates that mTOR plays an
important role in S6K regulation [49]. mTOR is a member of
the phosphoinositide kinase–related family of protein kinases.
It has been reported that mTOR phosphorylates S6K on T389
and activates S6K in vitro [50]. T389 is therefore the primary
rapamycin-sensitive phosphorylation site in vivo [49,50]. The
rationale for testing the chemopreventive efficacy of rapa-
mycin in the mouse lung tumor model is the observation
that the PI3K/Akt/mTOR pathway was activated in mouse
lung tumors [51]. A recent study has performed an immuno-
histochemical analysis of paraffin-embedded lung tissues
using phosphospecific antibodies against serine 473 of Akt,
serine 2448 of mTOR, and serine 9 of GSK3b [51]. It was
shown that Akt and mTOR (but not GSK3b) were activated
in lung tumors induced by NNK in A/J mice [51]. Another line
of evidence is the finding that blocking an enzyme (mTOR)
that acts further down the PI3K/Akt/mTOR pathway sensi-
tizes tumors to killing by conventional chemotherapy agents
[52]. In this study, we showed that rapamycin is chemo-
preventive in the mouse lung tumor carcinogenesis model
of A/J mice induced by BP. Administration of rapamycin re-
duced both lung tumor multiplicity and tumor load. This is the
first attempt, based on our knowledge, to test rapamycin in
animal models of lung carcinogenesis to establish the effi-
cacy of this compound as a chemopreventive agent of lung
cancer. Thus, the activation of the PI3K/Akt/mTOR pathway
in lung tumors is a new target for chemoprevention, especially
by agents that act on this pathway, namely rapamycin.
In summary, the results of this study show that poly-
phenon E, red ginseng, and rapamycin are novel lung chemo-
preventive agents that are effective in A/J mice. Interestingly,
the effects were substantially greater on tumor volume than
on multiplicity in mice treated with polyphenon E, ginseng, or
rapamycin, suggesting that themajor effect of these agents is
on later stages of the carcinogenic process. To follow up on
these observations, we are actively working on potential
mechanisms by which these agents may prevent lung tumor-
igenesis by conducting microarray studies and real-time
polymerase chain reactions of genes that are relevant to their
mechanisms of action, which are reported to be separate
once they are completed. Finding new and effective agents
that can prevent lung cancer is urgently needed because
cancer of the lungs remains the principal cause of cancer
deaths in the United States and because effective chemo-
prevention of this cancer type remains elusive. For example,
carotene, retinol, and vitamin E/C have been shown to have
little—or a negative—effect on human lung cancer develop-
ment in smokers [11]. Thus, polyphenon E, red ginseng, and
rapamycin are among the more promising new preventive
agents for lung cancer and should be considered for further
studies in animal models and clinical trials.
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